Atea Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Atea Pharmaceuticals, Inc. (AVIR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 358.50 thousand shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2022-11-07
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 358.50K shares, a 74.03% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 481.58K shares, a 52.88% decline year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-03-31 was 2.90M shares, a 31.13% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-09-30 was 206.00K shares, a 93.39% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|
| 2022-09-30 | 358.50K shares 10-Q · filed 2022-11-07 | 840.08K shares derived: sum of 2 quarters · filed 2022-11-07 | 3.74M shares 10-Q · filed 2022-11-07 |
| 2022-06-30 | 481.58K shares 10-Q · filed 2022-08-08 | 3.38M shares 10-Q · filed 2022-08-08 | |
| 2022-03-31 | 2.90M shares 10-Q · filed 2022-05-10 | ||
| 2021-09-30 | 206.00K shares 10-Q · filed 2022-11-07 | 1.23M shares derived: sum of 2 quarters · filed 2022-11-07 | 3.44M shares 10-Q · filed 2022-11-07 |
| 2021-06-30 | 1.02M shares 10-Q · filed 2022-08-08 | 3.23M shares 10-Q · filed 2022-08-08 | |
| 2021-03-31 | 2.21M shares 10-Q · filed 2022-05-10 | ||
| 2020-09-30 | 3.12M shares 10-Q · filed 2021-11-12 | 3.41M shares derived: sum of 2 quarters · filed 2021-11-12 | 3.41M shares 10-Q · filed 2021-11-12 |
| 2020-06-30 | 293.86K shares 10-Q · filed 2021-08-12 | 293.86K shares 10-Q · filed 2021-08-12 | |
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |